Media stories about Arena Pharmaceuticals (NASDAQ:ARNA) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.7386661514646 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Arena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per Share (americanbankingnews.com)
- Arena Pharmaceuticals (ARNA) Upgraded to “Outperform” by Wells Fargo (americanbankingnews.com)
- Arena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains Elusive (finance.yahoo.com)
- Arena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Arena Pharmaceuticals (ARNA) Earns “Buy” Rating from Cantor Fitzgerald (americanbankingnews.com)
Several research firms have recently weighed in on ARNA. Leerink Swann reaffirmed a “positive” rating and issued a $56.00 target price (up previously from $53.00) on shares of Arena Pharmaceuticals in a report on Wednesday, January 17th. BidaskClub lowered shares of Arena Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Needham & Company LLC raised shares of Arena Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $30.89 to $60.00 in a report on Tuesday, March 20th. JMP Securities upped their target price on shares of Arena Pharmaceuticals from $63.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. Finally, ValuEngine raised shares of Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 22nd. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Arena Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $52.25.
Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly earnings data on Wednesday, March 14th. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.30. Arena Pharmaceuticals had a negative net margin of 250.93% and a negative return on equity of 62.82%. The firm had revenue of $15.40 million for the quarter, compared to analyst estimates of $5.75 million. During the same quarter in the prior year, the firm earned $1.60 EPS. The company’s revenue was down 77.8% on a year-over-year basis. equities analysts predict that Arena Pharmaceuticals will post -2.74 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Arena Pharmaceuticals (NASDAQ:ARNA) Earning Somewhat Favorable Media Coverage, Report Shows” was published by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/04/03/arena-pharmaceuticals-arna-earning-somewhat-favorable-media-coverage-report-finds/2016562.html.
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.